Alcon (ALC) vs RxSight (RXST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alcon (ALC) has outperformed RxSight (RXST) over the past year, losing 16.4% versus a loss of 42.0%. Over five years, ALC leads with a -19.3% price change compared with -64.6% for RXST. Alcon is the larger company by market cap ($30.45 billion vs $199.6 million), about 152.5 times the size.
Alcon pays a dividend yielding 0.56%, while RxSight does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALC | RXST |
|---|---|---|
| Share price | $63.00 | $4.80 |
| Market cap | $30.45B | $199.65M |
| 1-day change | -0.30% | +3.23% |
| YTD return | -20.06% | -53.93% |
| 1-year return | -16.41% | -42.03% |
| 5-year return | -19.25% | -64.60% |
| P/E ratio (TTM) | 47.73 | — |
| Forward P/E | 15.89 | — |
| EPS (TTM) | $1.32 | $-1.14 |
| Dividend yield | 0.56% | 0.00% |
| Annual dividend | $0.353 | $0.00 |
| Revenue (latest FY) | $10.40B | — |
| Revenue growth (YoY) | +4.94% | — |
| Net income (latest FY) | $980.00M | — |
| Gross margin | 55.24% | — |
| Operating margin | 13.08% | — |
| Net margin | 9.42% | — |
| 52-week high | $87.64 | $13.22 |
| 52-week low | $61.84 | $4.48 |
| Distance from 52-week high | -28.12% | -63.69% |
| Analyst consensus | buy | none |
| Avg. price target upside | +32.62% | +57.71% |
| Average volume | 1.86M | 861.88K |
| Shares outstanding | 483.40M | 41.59M |
| Employees | 25,000 | 461 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alcon is about 152.5 times larger than RxSight by market value ($30.45B vs $199.65M).
- ALC has outperformed RXST by 25.6 percentage points over the past year.
About Alcon
ALC stock →Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.
Health Care · Ophthalmic Goods · 25,000 employees
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
ALC vs RXST FAQ
Which is bigger, Alcon or RxSight?
Alcon (ALC) is larger, with a market capitalization of $30.45B compared with $199.65M for RxSight (RXST).
Which stock has performed better over the past year, ALC or RXST?
ALC returned -16.41% over the past 12 months, compared with -42.03% for RXST (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Alcon or RxSight?
Alcon pays a dividend yielding 0.56%, while RxSight does not currently pay a regular dividend.
Are Alcon and RxSight in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.